Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

CATXPerspective TherapeuticsSigning up patients

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Pancreatic Ductal Adenocarcinoma · Gastric Cancer · Esophageal Cancer · Colorectal Cancer · Ovarian Cancer · Head and Neck Cancer · Sarcoma · Mesothelioma

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 4, 2026 · was worth 10, fading over time

    +4.8
Worry score5

Score over time

Stage
Phase 1/2
Patients
112 (planned)
Started
Apr 28, 2025
Main results expected
Jan 31, 2028
Fully finished
May 28, 2032
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Determination of safety and tolerability of [203Pb]Pb-PSV359

    Measured over: 30 days (±1day) post dose

  • Determination of safety and tolerability of [212Pb]Pb-PSV359

    Measured over: Up to 3 years

  • To determine the recommended phase 2 dose of [212Pb]Pb-PSV359

    Measured over: Up to approximately 6 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 10, now 4.8, since 2026-09-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06710756 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06710756) ↗